CEO: Saji Wickramasekara
Headquarters: San Francisco
Benchling offers a unified life sciences research and development cloud software platform to centralize and standardize all R&D data. The platform is built for the complexity of large molecules. Users can model and interlink anything from sequences to cell lines to reagents, and model any experimental process as a digital, step-by-step workflow. They can create custom dashboards to track any R&D data, adjust Benchling without code and integrate any instrument or software to automate manual data tasks.
In May, Benchling closed a $50 million Series D funding round led by New York’s Alkeon Capital Management. At the time, CEO Saji Wickramasekara told Forbes that the investment brought Benchling’s total funding to $114 million and a valuation of $850 million.
Benchling’s customers are in industries ranging from pharmaceuticals and fuels to agriculture and food, and they include companies at the forefront of COVID-19 research, such as Gilead Sciences, Regeneron Pharmaceuticals and Mammoth Biosciences.